|
Market Closed -
Nasdaq
04:00:00 2026-08-13 pm EDT
|
5-day change | 1st Jan Change | ||
| 213.68 USD | -0.46% |
|
+1.69% | +17.00% |
| Aug. 12 | UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating | MT |
| Aug. 12 | Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AXSM Stock
- Consensus Axsome Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
